Cassio Murilo Hidalgo-Filho

机构：Harvard University, Instituto do Câncer do Estado de São Paulo, Dana-Farber Cancer Institute, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Hospital Sírio-Libanês

发表论文 7 篇 · 总被引 1 次 · h-index 1

代表论文

• Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies (2026 · Journal of Clinical Oncology · 被引 1)
• Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report (2025 · ecancermedicalscience · 被引 1)
• Impact of STK11 / KEAP1 / SMARCA4 co-mutations in RAS-activated KRAS wild-type metastatic NSCLC treated with immune checkpoint inhibitors. (2026 · Journal of Clinical Oncology)
• Genomic determinants of resistance to BRAF/MEK inhibitors in BRAF V600E –mutant non–small cell lung cancer. (2026 · Journal of Clinical Oncology)
• Prognostic significance of STK11, KEAP1, and NFE2L2- mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy. (2026 · Journal of Clinical Oncology)
• Clinico-genomic landscape and prognostic impact of APC/CTNNB1 oncogenic alterations in non–small cell lung cancer. (2026 · Journal of Clinical Oncology)